All In Biotech

Drug Trial Radar · NCT04178447

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

An Open-label, Multi-center Trial to Evaluate the Pharmacokinetic Profile of Glepaglutide After a Single Subcutaneous Injection in Subjects With Varying Degrees of Renal Function

Last checked: Nov 20, 2026Latest source record: Nov 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Dec 10, 2019

Primary completion

Jul 14, 2020

Study completion Jul 14, 2020

Sponsor

Lead sponsor
Zealand PharmaIndustry
Sponsor type
Industry
First posted
Nov 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is two stage design, open-label, multi-center, non-randomized trial evaluating the PK of a single, subcutaneous dose of 10 mg glepaglutide in subjects with varying degrees of renal function. The renal function will be calculated by the estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) equation.

Conditions

  • Renal Impairment

Interventions

  • GlepaglutideDrug

    Single dose of Glepaglutide 10 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic VariablesTime frame: 11 days

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Fázis I-es Klinikai Farmakológiai

    Budapest, Hungary

  • Szent Imre Egyetemi Oktatókórház

    Budapest, Hungary

  • Specjalistyczne Centrum Medyczne - Prywatny Szpital

    Krakow, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.